Erastin: A Ferroptosis Inducer Targeting RAS/BRAF-Mutant Tumor Cells

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis, a distinct form of iron-dependent, non-apoptotic cell death, in tumor cells with RAS or BRAF mutations (ApexBio). It acts by modulating the voltage-dependent anion channel (VDAC) and inhibiting the cystine/glutamate antiporter system Xc⁻, leading to redox imbalance and cell death (Liu et al., 2021). Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with mild heat. Standard protocols use 10 μM Erastin for 24 hours on engineered or HT-1080 tumor cells. Its specificity for RAS/BRAF-mutant models makes Erastin a gold-standard reagent for ferroptosis and oxidative stress research (related article).

Biological Rationale

Ferroptosis is a regulated, iron-dependent form of cell death that is morphologically, biochemically, and genetically distinct from apoptosis, necroptosis, and autophagy (Liu et al., 2021). Unlike caspase-dependent apoptosis, ferroptosis is triggered by lethal lipid peroxidation and loss of redox homeostasis. Tumor cells harboring oncogenic mutations in the RAS family (KRAS, HRAS) or BRAF are especially vulnerable to ferroptosis, owing to altered metabolic and antioxidant pathways. Erastin exploits this vulnerability, enabling researchers to selectively induce cell death in these cancer cell subsets. This selectivity allows for precise experimental dissection of the RAS-RAF-MEK pathway’s impact on cell survival under oxidative stress (see comparison).

Mechanism of Action of Erastin

Erastin targets two key molecular pathways:

• VDAC Modulation: Erastin binds and modulates the voltage-dependent anion channel (VDAC) on the outer mitochondrial membrane, increasing mitochondrial permeability and promoting ROS generation (Liu et al., 2021).
• System Xc⁻ Inhibition: Erastin inhibits the cystine/glutamate antiporter system Xc⁻ (encoded by SLC7A11), blocking cystine uptake and glutathione synthesis. This leads to glutathione depletion and impaired detoxification of lipid peroxides, tipping the redox balance toward ferroptosis.

These actions result in the accumulation of toxic lipid peroxides and iron-dependent oxidative damage, culminating in cell death that is independent of caspase activation or necroptotic machinery. Notably, Erastin-induced ferroptosis is unaffected by RIPK3 or MLKL status, distinguishing it from necroptosis (Liu et al., 2021).

Evidence & Benchmarks

• Erastin induces ferroptosis in HT-1080 fibrosarcoma cells at 10 μM for 24 hours, causing significant cell death via ROS accumulation (ApexBio).
• Ferroptosis induced by Erastin is iron- and ROS-dependent and is not rescued by caspase inhibitors, confirming a caspase-independent mechanism (Liu et al., 2021).
• Erastin’s cytotoxicity is selective for cells with oncogenic RAS or BRAF mutations, sparing wild-type cells under matched conditions (see review).
• Erastin is insoluble in water and ethanol but soluble in DMSO at concentrations ≥10.92 mg/mL with gentle warming, facilitating preparation for in vitro assays (ApexBio).
• Erastin’s effect is not confounded by necroptosis pathway interference (e.g., RIPK3-MLKL axis), as shown in necroptosis-deficient cells (Liu et al., 2021).

Applications, Limits & Misconceptions

Erastin is routinely used in:

• Ferroptosis research to dissect non-apoptotic, iron-dependent cell death mechanisms.
• Cancer biology studies targeting RAS or BRAF-driven tumor models.
• Oxidative stress assays and validation of therapeutic strategies exploiting redox vulnerabilities.

It is a reference tool for distinguishing ferroptosis from necroptosis or apoptosis. For a comprehensive comparison with other ferroptosis inducers and workflows, see Ferroptosis as a Translational Frontier, which this article extends by focusing on Erastin’s selectivity and workflow integration.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necroptosis; its cell death effects are caspase- and RIPK3-independent.
• It is not stable in solution for long-term storage; fresh DMSO solutions should be prepared prior to each experiment (ApexBio).
• Water and ethanol are unsuitable solvents; only DMSO at ≥10.92 mg/mL with mild warming yields effective solutions.
• Erastin’s selectivity is limited to RAS/BRAF-mutant cells; wild-type cells are less sensitive under standard conditions.
• It does not activate immune cell death pathways directly, unlike certain viral inducers of necroptosis (Liu et al., 2021).

Workflow Integration & Parameters

For most in vitro applications, Erastin is dissolved in DMSO at ≥10.92 mg/mL with gentle warming and used at a final concentration of 10 μM, typically for 24 hours, on engineered human tumor cells or HT-1080 fibrosarcoma cells. Solutions should be freshly prepared to ensure potency. Erastin should be stored as a solid at -20°C for long-term stability. The B1524 kit provides batch-tested material suitable for reproducible results.

To maximize assay fidelity, pair Erastin treatment with appropriate controls (e.g., DMSO vehicle, iron chelators, and ROS scavengers) and validate cell death using ferroptosis-specific readouts (lipid peroxidation assays, glutathione depletion, and iron dependency). For troubleshooting and advanced workflows, see Erastin and the Next Frontier of Ferroptosis Research, which this article updates by detailing benchmark protocols and stability caveats.

Conclusion & Outlook

Erastin is a robust, well-characterized ferroptosis inducer that enables precise study of iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant tumor models. Its mechanism—VDAC modulation and system Xc⁻ inhibition—provides a reliable platform for dissecting oxidative stress responses in cancer biology. While Erastin’s selectivity and solubility constraints define its optimal use, its value in translational and preclinical research is uncontested. For future directions, integration of Erastin into combinatorial screens and in vivo models will further illuminate ferroptosis’ therapeutic potential.